Motivation
Coronary artery disease (CAD) is the #1 cause of death world-wide. Stents are widely used to treat CAD accounting for 2 million percutaneous coronary interventions (PCIs)/Year.
The PCI problem: Missed complications drive poor outcomes
- 30% stent failure rate due to improper stent placement.
- Undetected Geographic Miss (GM) and Stent Edge Dissections (SED) cause stent failures.
- Current imaging (IVUS/OCT) are time consuming, expertise dependent and often miss subtle complications.
There is no rapid, reliable way to detect GM/SED during PCI today.
i3 believes that, with its novel imaging technologies many of those failed procedures could be avoided which has the potential to save millions in healthcare cost and improve clinical patient outcomes.
i3 Leadership
R. Scott Jones - Chairman & CEO
Farouc A. Jaffer, MD, PhD - Co-Founder
Farouc A. Jaffer, MD, PhD - Co-Founder
25+ years in medical device sector including leadership of the GE Cardiovascular Business. Successful exits from start-ups to 7,000 employees.
Farouc A. Jaffer, MD, PhD - Co-Founder
Farouc A. Jaffer, MD, PhD - Co-Founder
Farouc A. Jaffer, MD, PhD - Co-Founder
Acclaimed interventional cardiologist/ researcher in biological imaging. Professor of medicine, Director of Coronary Intervention, MGH/Harvard Medical School.
Vasilis Ntziachristos, PhD - Co-Founder
Philipp Rauschendorfer, PhD - Chief Scientific Officer
Philipp Rauschendorfer, PhD - Chief Scientific Officer
Acclaimed researcher in biological imaging, Professor of Medicine/Electrical Engineering, Technical University of Munich and Chair for Biological Imaging (CBI).
Philipp Rauschendorfer, PhD - Chief Scientific Officer
Philipp Rauschendorfer, PhD - Chief Scientific Officer
Philipp Rauschendorfer, PhD - Chief Scientific Officer
Biomedical R&D Engineer specialized in medical imaging. Successful researcher in the field of intravascular imaging Technical University of Munich and MGH/Harvard Medical School.